Pancreatic tumours account for 2.6% of all newly diagnosed cancers in the UK with ∼8000 new diagnoses and deaths each year, making it the fifth most common cause of cancer death in the UK ([@bib3]). Worldwide there are an estimated 279 000 new cases per year. It has a very poor prognosis, with few patients eligible for potentially curative surgery, leading to a 5-year survival of around 3% ([@bib26]). The incidence increases with age, with over 75% of new cases occurring in those aged 65 and over. Most tumours originate from the exocrine part of the pancreas. Endocrine tumours are rare but generally have a much more favourable prognosis. Despite the emergence of promising biomarkers for diagnosis there are no screening tests currently available, so diagnosis depends upon presentation with symptoms.

The symptoms of primary pancreatic cancer have only been described in secondary care studies. It occurs rarely in primary care: a full time general practitioner (GP) would see on average only one case every 5 years ([@bib21]). Studies have mostly been retrospective surgical case series, with the potential for recall bias; perforce, they study patients late in the natural course of their disease. Abdominal pain is reported in up to 80% of patients ([@bib28]). Obstructive jaundice, which occurs when the biliary tract becomes blocked by the tumour, occurs in 16--85%: ([@bib15]; [@bib20]; [@bib19]; [@bib7]; [@bib31]; [@bib4]) it is usually a feature of advanced disease. Weight loss is also reported in 3--82%, again generally denoting advanced disease ([@bib15]; [@bib20]; [@bib7]; [@bib4]). Pancreatitis and thrombo-phlebitis have also been described ([@bib2]; [@bib24]) Diabetes may follow if pancreatic damage is considerable ([@bib5]). Other symptoms, such as loss of taste, pruritus, psychological disturbances or skin changes, have been reported for up to 2 years before onset of pain or jaundice ([@bib24]).

UK guidance for the selection of patients for urgent investigation of suspected cancer has no specific section relating to pancreatic cancer: instead, recommendations for oesophageal, gastric and pancreatic cancer are merged, with criteria for upper gastrointestinal endoscopy predominant ([@bib22]). Symptoms potentially representing one of these three cancer sites recommended for urgent investigation are obstructive jaundice, persistent vomiting, anaemia or an unexplained loss of weight. In a recent audit of 345 upper gastrointestinal urgent referrals based on these recommendations in London, 36 (11.4%) upper gastrointestinal cancers were identified, 13 being pancreatic ([@bib23]). Most were advanced disease. The authors called for better selection of patients for investigation: this requires study of the symptoms of pancreatic cancer in primary care. We sought to identify features of pancreatic cancer, and to quantify their risk, in patients presenting to primary care.

Materials and methods
=====================

This was a case--control study using data from the General Practice Research Database (GPRD) in the UK. The GPRD maintains an anonymised copy of participating practices\' medical records: these contain full details of the patient, including all consultations, recorded symptoms, investigations and diagnoses. The data are subject to stringent checks on validation and quality, and they are regarded as high quality in terms of accuracy and completeness and validity of diagnoses ([@bib11]; [@bib14]). We have previously used similar methods for several cancer diagnostic studies ([@bib10]).

Identification of cases and controls
------------------------------------

A list of 25 pancreatic tumour diagnostic codes (available from the authors) was collated from the GPRD master code library. This has ∼100 000 codes covering all events in primary care. Some codes specifically identified the histological subtype, but most were unspecified, such as 'malignant neoplasm of pancreas\'. Staff from the GPRD identified all patients aged 40 years and over with a pancreatic tumour diagnosed between 1st January, 2000 and 31st December, 2009 and with at least 1 year of data meeting their quality standards before the first diagnostic code. For each case, the GPRD identified up to five controls, matched to the case by year of birth, sex and practice and randomly selected using a computer-generated sequence. We chose five controls for maximum power within the GPRD\'s constraints as to total database size. We excluded cases and controls if they had no consultations in the year before diagnosis in the case (the index date). Controls were excluded if they had ever had pancreatic cancer.

Selection of possible features of pancreatic cancer
---------------------------------------------------

We studied all symptoms, physical signs or abnormal investigations compiled from the pancreatic cancer literature, supplemented by discussion with two pancreatic cancer charities (full list available from authors). For simplicity, these are called 'features\' from now on. Libraries of codes relating to these were collated. We also identified all codes for fractures, as a test for any recording bias between cases and controls (making the assumption that the fracture rate would be approximately equal). Occurrences of these features in the year before the index date were identified. Features were only retained for further study if they occurred in ⩾5% of cases or controls. Repeat attendances with the same symptom were also retained if the subsequent consultation also occurred in ⩾5% of cases or controls. We defined new-onset diabetes as a code for diabetes, or a random blood glucose above the local laboratory\'s normal range, without similar codes more than 1 year before the index date. For laboratory tests, we considered patients without a test to be the same status as those with a normal result, making our binary variable abnormal result/ no abnormal result. We defined abnormal liver function as any liver enzyme above the normal range, and raised inflammatory markers as either abnormal erythrocyte sedimentation rate or C-reactive protein, as there were too few plasma viscosity results.

Analysis
--------

Univariable analysis of differences between cases and controls was undertaken using conditional logistic regression to account for the matching. Variables independently associated with pancreatic cancer with a *P*-value \<0.1 were entered into multivariable analyses. Multivariable regressions were performed in stages, initially collecting similar variables together, such as those reflecting abdominal pain. Significant variables then entered a second stage, grouping variables into abdominal symptoms, other symptoms, physical signs and investigations. For these two stages, a threshold *P*-value of \<0.05 was used. The final model was derived from all variables surviving the earlier stage regressions, and used a threshold *P*-value of \<0.01. All rejected variables were checked to see if they added anything to the final model. Lastly, nine clinically plausible interactions were tested.

Calculation of positive predictive values (PPVs)
------------------------------------------------

It was possible to calculate PPVs for the risk of pancreatic cancer in patients consulting in primary care using Bayes\' theorem ([@bib16]). In this, the posterior odds of disease=the prior odds × the likelihood ratio. For the prior odds we used the age-specific national incidence rate of pancreatic cancer for 2008 ([@bib3]). As all 3635 cases analysed had consulted in primary care, but only 16 459 of 17 913 (92.1%) controls had consulted in the study period, we divided the posterior odds by 0.921 to give predictive values for the consulting population. Analyses were performed using Stata (version 11) ([@bib27]).

Results
=======

We were initially supplied with 3647 cases and 17 977 controls, as 1207 cases could not be matched to five controls. The application of exclusions is shown in [Figure 1](#fig1){ref-type="fig"}.

Of the 3635 cases included in the analyses, 98 (2.7%) had a specific code for an endocrine tumour, though 2342 (64.2%), had a generic label and some of these may have been endocrine. The demographic features of cases are shown in [Table 1](#tbl1){ref-type="table"}, and the univariable results for selected clinical features are shown in [Table 2](#tbl2){ref-type="table"}. Sixty five (1.8%) of cases and 297 (1.8%) of controls had a record of a fracture. In the year before diagnosis, cases presented to primary care twice as frequently as controls: cases median 18; interquartile range (IQR) 11, 27: controls median 9 (IQR) 4, 15.

Multivariable analysis results are shown in [Table 3](#tbl3){ref-type="table"}. One antagonistic interaction term is included: abdominal pain with jaundice. This can probably be explained clinically by an alternative diagnosis of gallstones, which also may have abdominal pain and jaundice as presenting features. External interaction terms (testing whether features were more or less strongly associated with cancer according to age, sex and smoking habits) were not significant.

[Figure 2](#fig2){ref-type="fig"} shows PPVs for pancreatic cancer for the symptoms shown to be independently associated in multivariable analysis -- individually, when repeated and in combination with another symptom for patients aged ⩾60 years of either sex. This age was chosen to allow over 80% of the pancreatic cancer population to be shown in a single figure. For jaundice with constipation, diarrhoea, loss of weight or malaise, more than 40 cases but no controls had the combination; while strictly speaking undefined, the PPV must logically be very high and so it has been set as \>10%. One subgroup analysis by age was undertaken. Patients aged ⩾70 (the older half of the cohort) had PPVs for most symptoms 1.5 to 4.5 times higher than those for patients under 70 years of age.

Discussion
==========

Summary of main findings
------------------------

This is the first study of the clinical features of pancreatic cancer in primary care. Most of the symptoms reported from secondary care studies were also strongly associated with pancreatic cancer in primary care. However, the risk of pancreatic cancer with these features -- other than jaundice -- was low, reflecting the rarity of pancreatic tumours and that many of the symptoms are common in benign conditions. The risk of an underlying pancreatic cancer with these symptoms was higher in older patients, and in patients with multiple symptoms.

Strengths and limitations of the study
--------------------------------------

This study is large, and uses primary care data. This is crucial: selection of patients for investigation is performed by clinicians in primary care, so primary care data must be used to illuminate the selection process. The GPRD is considered by many to be the \'gold standard\' of longitudinal patient databases from primary care. It has been used in nearly 1000 research papers published in peer-reviewed journals and its validity has been well documented ([@bib12]; [@bib13]; [@bib6]; [@bib11]; [@bib14]). The patient population in the database is also broadly representative of the UK population. Additionally, laboratory results are transmitted directly to the database, allowing us to use the local normal range to identify abnormal results.

We could not check the accuracy of diagnosis in the cases by histology, or determine the staging. Linkage to cancer registries is now possible, though only for a part of the GPRD. Most cases had multiple records of a pancreatic neoplasm. It is unlikely that such a serious disease would be recorded incorrectly with any frequency.

The most significant limitation of the study is that we had to rely upon the accurate recording by GPs of both symptoms and diagnoses. Under-recording of symptoms or signs may have led to some features, which may be genuinely associated with pancreatic cancer, such as deep vein thrombosis or steatorrhoea, not being identified in this study. One particular concern is that symptoms may be recorded in an inaccessible part of the GPRD -- the so-called 'free-text\' area. This is possible, though a recent study of ovarian cancer identified relatively little hidden data in these fields ([@bib29]. However, when calculating likelihood ratios and PPVs, under-recording is only important if the proportion of under-recording was differentially higher in either cases or controls. We have no evidence to suggest this is the case.

Comparison with existing literature
-----------------------------------

The prevalence of the most common symptoms of pancreatic cancer was lower than in previous secondary care studies ([@bib17]; [@bib2]; [@bib8]; [@bib9]; [@bib25]). This may well reflect different symptom experience early in the disease -- especially in primary care. There are two possible alternative explanations. The first is under-recording of symptoms, as discussed earlier; the second is that most previous studies directly interviewed patients after diagnosis. Such methods may be subject to recall bias and usually uncover higher rates of symptom reporting than do studies using indirect methods such as ours. One UK questionnaire-based study, which compared symptom recording in pancreatic disease by GPs to symptom recording by health professionals in secondary care, found prevalence figures similar to this study ([@bib30]). Our finding of more frequent attendances mirrors reports in the National Cancer patient Experience Survey, where 41% of pancreatic cancer patients reported consulting their GP at least three times before diagnosis ([@bib18].

Implications for clinical practice and future research
------------------------------------------------------

Our results should help GPs decide which patients to refer for further investigation. A fifth of patients over 60 years with recorded jaundice will have pancreatic cancer: this figure would justify urgent referral. Current NICE guidance recommends urgent referral only for obstructive jaundice, but the results from this study would suggest that investigation for jaundice *per se* is warranted, unless there is a clear alternative cause ([@bib22]). Even if no malignancy is uncovered by investigation, a common alternative explanation for jaundice is stones in the biliary system, and these are also worth identifying without undue delay. Similarly, loss of weight had moderate PPVs when accompanied by a second symptom from [Table 3](#tbl3){ref-type="table"}. Arguably, such patients could also be considered for investigation. One problem is that ultrasonography is excellent at visualising the biliary tree, but CT scanning is preferred for imaging the pancreas itself -- thus, non-jaundiced patients would probably require the latter form of imaging. Although more expensive than ultrasonography, CT scanning may identify a cause for the symptoms should the pancreas appear normal.

Conclusion
==========

Although current mortality from pancreatic cancer is very high in the UK, other European countries have better outcomes from the cancer ([@bib1]). It is not known if these better outcomes arise from improved diagnostics or better treatment, or both, but it gives some hope that the current dismal prognosis can be improved somewhat. Our figures can guide GPs in selection of patients for urgent investigation. Even though no new major findings have emerged, this study provides primary care evidence for the forthcoming revision of the UK NICE referral guidance.
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![Application of exclusion criteria for cases and matched controls. Conditional logistic regression requires a minimum of one case and one matched control in each set, so if the case or all the controls are excluded than the remaining set members must also be discarded.](bjc2012190f1){#fig1}

![Positive predictive values (95% CIs) for pancreatic cancer in men and women aged over 60 for individual risk markers and for pairs of risk markers in combination. (1) The top figure in each cell is the positive predictive value when both features are present. The two smaller figures represent the 95% CIs for the positive predictive value. These have not been calculated when any cell in the 2 × 2 table was below 5 (invariably this was because too few controls had both features). (2) The yellow shading is for pairs of symptoms with a positive predictive value over 1% the amber shading is when the positive predictive value is above 2.0%, and the red shading is for positive predictive values above 5.0%. (3) The jaundice/jaundice intersect is the positive predictive value for pancreatic cancer when a patient has attended at least twice with jaundice. The same is true for abdominal pain and back pain.](bjc2012190f2){#fig2}

###### Characteristics of patients in primary care with pancreatic cancer (cases) and matched controls. Figures are number (percentage)

                **Cases**                               
  ------------- ------------- ------------ ------------ -------------
  40--49        107 (2.9)     43 (40.2)    64 (59.8)    422 (2.6)
  50--59        529 (14.5)    234 (44.2)   295 (55.8)   2239 (13.6)
  60--69        829 (22.8)    369 (44.5)   460 (55.5)   3755 (22.8)
  70--79        1212 (33.4)   654 (53.9)   558 (46.1)   5702 (34.6)
  80 and over   958 (26.4)    592 (61.8)   366 (38.2)   4341 (26.4)

###### Frequency of selected features in cases and controls in the whole study population

  **Clinical feature**           **Cases,** ***n*** **(%),** ***n*****=3635**   **Controls,** ***n*** **(%),** ***n*****=16 459**   **LR** **(95% CI)**    **PPV in percent^a^ (95% CI)**
  ------------------------------ ---------------------------------------------- --------------------------------------------------- ---------------------- --------------------------------
  *Symptoms*                                                                                                                                                
   Abdominal pain                1540 (42.4)                                    1004 (6.1)                                          7.0 (6.5--7.5)         0.2 (0.19--0.22)
   Nausea/ vomiting              590 (16.2)                                     408 (2.5)                                           6.6 (5.8--7.4)         0.19 (0.17--0.21)
   Back pain                     452 (12.4)                                     1007 (6.1)                                          2.0 (1.8--2.3)         0.06 (0.05--0.07)
   Constipation                  427 (11.8)                                     555 (3.4)                                           3.5 (3.1--3.9)         0.1 (0.09--0.11)
   Diarrhoea                     385 (10.6)                                     539 (3.3)                                           3.2 (2.9--3.7)         0.09 (0.08--0.11)
   Weight loss                   353 (9.7)                                      105 (0.6)                                           15.2 (12.3--18.9)      0.44 (0.36--0.55)
   Malaise                       187 (5.1)                                      197 (1.2)                                           4.3 (3.5--5.2)         0.12 (0.1--0.15)
                                                                                                                                                           
  *Signs*                                                                                                                                                   
   Jaundice                      1110 (30.5)                                    10 (0.1)                                            502.6 (269.9--935.7)   12.9 (7.89--27.1)
                                                                                                                                                           
  *Diseases*                                                                                                                                                
   New-onset diabetes            804 (22.1)                                     1201 (7.3)                                          3.0 (2.8--3.3)         0.09 (0.08--0.10)
                                                                                                                                                           
  *Investigations*                                                                                                                                          
   Abnormal liver function       1834 (50.5)                                    1506 (9.2)                                          5.5 (5.2--5.8)         0.16 (0.15--0.17)
   Low haemoglobin               728 (20.0)                                     978 (5.9)                                           3.4 (3.1--3.7)         0.1 (0.09--0.11)
   Raised inflammatory markers   892 (24.5)                                     734 (4.5)                                           5.5 (5.0--6.0)         0.16 (0.15--0.17)

Abbreviations: CI=confidence interval; LR=likelihood ratio; PPV=positive predictive value.

PPV in the consulting population.

###### Multivariable analysis of the clinical features of pancreatic cancer

  **Variable**                    **Odds ratio (95% CI)**   ***P*****-value**
  ------------------------------- ------------------------- -------------------
  *Symptoms*                                                 
   Loss of weight                 15 (11, 22)               \<0.001
   Abdominal pain                 5 (4.4, 5.6)              \<0.001
   Nausea or vomiting             4.5 (3.5, 5.7)            \<0.001
   Constipation                   2.2 (1.7, 2.8)            \<0.001
   Malaise                        2.4 (1.6, 3.5)            \<0.001
   Diarrhoea                      1.9 (1.5, 2.5)            \<0.001
   Back pain                      1.4 (1.1, 1.7)            0.004
                                                             
  *Signs*                                                   
   Jaundice                       1000 (430, 2500)          \<0.001
                                                             
  *Diseases*                                                
   Diabetes                       2.1 (1.7, 2.5)            \<0.001
                                                            
  *Interaction term*                                         
   Jaundice with abdominal pain   0.13 (0.05, 0.35)         \<0.001

Abbreviation: CI=confidence interval.
